Background {#Sec1}
==========

The prevalence of recognized chronic kidney disease (CKD) is increasing globally \[[@CR1]\]. Patients with CKD have higher mortality rates and reduced quality of life relative to the general population \[[@CR2]\]. They are also at a disproportionally higher cardiovascular risk, and most patients with CKD die of cardiovascular disease (CVD) rather than progress to end-stage renal disease (ESRD) \[[@CR3]\]. The importance of finding modifiable risk factors that slow CKD progression or reduce cardiovascular risk cannot be understated.

Because low glomerular filtration rate (GFR) leads to hyperuricemia, CKD is associated with hyperuricemia and gout \[[@CR4]\]. Hyperuricemia has also consistently been associated with incident CKD, though its association with progression of CKD has been less clear \[[@CR5]-[@CR27]\].

Currently, urate-lowering therapy (ULT) is only used for patients with clinical evidence of crystal deposition such as gout or urolithiasis \[[@CR28]\]: routine prophylaxis of asymptomatic hyperuricemia is not recommended in current guidelines. This systematic review summarizes evidence from randomized controlled trials that examined whether treating patients with stages 3-5 CKD improves renal and cardiovascular outcomes.

Methods {#Sec2}
=======

Study selection {#Sec3}
---------------

We included studies if their selection criteria specified estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m^2^ or their baseline mean eGFR or serum creatinine were \<60 ml/min/1.73 m^2^ or \>137 μmol/L for men, and \>104 μmol/L for women, respectively (\>1.55 mg/dL for men and \>1.18 mg/dL for women) \[[@CR29]\]. Any pharmacologic therapy given to lower uric acid was considered a suitable intervention. These included allopurinol, febuxostat, probenecid, sulfinpyrazone, benzbromarone, pegloticase and rasburicase. We included studies in which the comparator was placebo, usual therapy or an alternative drug. Outcomes of greatest interest were: serum creatinine level, eGFR, proteinuria, incidence of ESRD, incidence of cardiovascular events and cardiovascular mortality. Other outcomes were: serum uric acid level, blood pressure (diastolic and systolic), markers of inflammation (C-reactive protein levels), all-cause mortality, adverse events and serious adverse events. We included only RCTs and quasi-RCTs. We accepted any estimate of GFR, whether derived from serum creatinine and demographic variables, or from directly-measured creatinine or isotope clearance. We followed a prespecified protocol but this was not registered.

Finding relevant studies {#Sec4}
------------------------

In the primary search, citations were compiled from the following electronic databases: Ovid MEDLINE (1966-June 2013), Ovid EMBASE (1980-June 2013), CENTRAL (June 2013) and Web of Science (June 2013) using search strategies detailed in the Additional file [1](#MOESM1){ref-type="media"}. We reviewed the Cochrane Collaboration's protocol and adapted some of their search terms \[[@CR30]\]. The first arm of our search strategy included terms such as: kidney disease, renal insufficiency and renal replacement therapy as well as further synonyms and key words. These were combined with the second arm of our strategy comprising of terms such as allopurinol, gout suppressants, urate oxidase and further descriptors related to ULT. The citations were downloaded into Endnote, version X7 (Thompson ISI Research-Soft, Philadelphia, PA) and duplicate citations removed.

To further identify relevant studies, a secondary search was performed, making use of reference lists of previous narrative reviews \[[@CR31]-[@CR33]\] and of studies identified in the primary search, PubMed 'Related Articles' feature, published abstracts from two recent American Society of Nephrology (2010-2012) and International Society of Nephrology meetings (2010-2012), internet searches using Google Scholar, and trial registers from National Institute of Health and Current Controlled Trials. We also identified seven studies \[[@CR34]-[@CR40]\] from two recently published systematic reviews on a similar question \[[@CR41],[@CR42]\].

Two authors (TK, MG) completed the first phase of screening using titles and abstracts (kappa of 0.84). Agreement for the second phase of screening, using full-text manuscripts, was lower at a kappa of 0.41. All disagreements for both phases were resolved by consensus.

Data abstraction and quality assessment {#Sec5}
---------------------------------------

Two authors (TK and MG) independently extracted data for each included study using standardized forms. Subsequently, quality assessment was also completed in duplicate (TK, MG) using the Cochrane Collaboration's Higgins Risk of Bias Assessment Tool \[[@CR43]\]. Disagreements from both data abstraction and quality assessment were resolved through consensus. All the non-English language studies were written in Chinese; data was extracted and quality assessed by one author (TK), with the assistance of a translator.

Data synthesis and meta-analysis {#Sec6}
--------------------------------

Given the heterogeneity in duration of follow up and study comparators, we decided to meta-analyze studies greater than 3 months in duration that compared allopurinol to inactive control \[[@CR34],[@CR36]-[@CR40],[@CR44]-[@CR48]\].

We used a random-effects model within Comprehensive Meta-analysis (Englewood NJ). Two of the studies did not report GFR estimates \[[@CR46],[@CR48]\]: we used serum creatinine and demographic information from the studies, to estimate mean eGFR. The equations utilized were Modification of Diet in Renal Disease (MDRD) with Chinese coefficients where appropriate \[[@CR49]\].

Results {#Sec7}
=======

Primary electronic database searches identified 5994 citations, which was reduced to 5497 citations by deduplication. We retrieved 32 full-text manuscripts from the electronic search and a further eight from secondary sources, of which 19 studies were relevant (Figure [1](#Fig1){ref-type="fig"}).Figure 1Flow diagram.

Description of studies {#Sec8}
----------------------

The 19 studies, published between 1998 and 2012, randomized 992 participants with duration of follow-up ranging from 2 days to 24 months; 16 were parallel group and 3 were crossover design (Table [1](#Tab1){ref-type="table"}). The studies originated from 10 different countries, including the United States, United Kingdom, Iran, France, Italy, Greece, Spain and China. Most were single-centre and had relatively small sample sizes with short duration of follow up. Populations were variable and half the studies did not report usage of baseline renin-angiotensin-aldosterone system (RAAS) blockade (Table [2](#Tab2){ref-type="table"}).Table 1**Study characteristics**First author (Ref No.)Year of publicationJournalLocation of trialStudy designDuration of follow-upSample sizeTreatmentControlKatholi \[[@CR51]\]1998American Journal of Kidney DiseasesSpringfield, IllinoisParallel Group RCT with 2x2 factorial design2 days39AllopurinolPlaceboPerez-Ruiz \[[@CR56]\]1999Journal of Clinical RheumatologyPais Vasco, SpainParallel Group RCT9-12 months36BenzbromaroneAllopurinolKamper \[[@CR50]\]2001Clinical TransplantationHerlev, DenmarkCross-over RCT2 weeks26LosartanNo treatmentSchmidt \[[@CR53]\]2001Nephrology Dialysis TransplantationVienna, AustriaCross-over RCT3 weeks13LosartanEnalaprilDoehner \[[@CR35]\]2002CirculationLondon, UKCross-over RCT2 weeks14AllopurinolPlaceboChanard \[[@CR54]\]2003Nephrology Dialysis TransplantationThree centres in FranceParallel Group RCT2 months48AmlodipineTertatololSiu \[[@CR48]\]2006American Journal of Kidney DiseasesHong Kong, ChinaParallel Group RCT12 months54AllopurinolNo treatmentLiu \[[@CR36]\]2007China PharmacyGuangzhou and Luzhou, ChinaParallel Group RCT12 months47AllopurinolNo treatmentSarris \[[@CR34]\]2007Nephrology Dialysis TransplantationAthens, GreeceParallel Group RCT12 months36AllopurinolNo treatmentLei \[[@CR40]\]2009Shaanxi Medical JournalXi'an, ChinaParallel Group RCT12 months57AllopurinolNo treatmentMalaguarnera \[[@CR55]\]2009Expert Opinion PharmacotherapyCatania, ItalyParallel Group RCT2 months38RasburicasePlaceboNouri-Majalan \[[@CR52]\]2009Vascular Health and Risk ManagementYazd, IranParallel Group RCT5 days60Allopurinol and vitamin ENo treatmentDeng \[[@CR37]\]2010Journal of Practical MedicineBeijing, ChinaParallel Group RCT12 months68AllopurinolNo treatmentGoicoechea \[[@CR44]\]2010Clinical Journal of American Soc of NephMadrid, SpainParallel Group RCT24 months113AllopurinolNo treatmentMomeni \[[@CR46]\]2010Iranian Journal of Kidney DiseasesIsfahan, IranParallel Group RCT4 months44AllopurinolPlaceboShen \[[@CR38]\]2010China Foreign Medical TreatmentChengdu, ChinaParallel Group RCT12 months52AllopurinolNo treatmentKao \[[@CR45]\]2011Journal of American Soc of NephDundee, UKParallel Group RCT9 months67AllopurinolPlaceboTan \[[@CR39]\]2011Modern HospitalGuangzhou, ChinaParallel Group RCT24 months140AllopurinolNo treatmentShi \[[@CR47]\]2012Kidney and Blood Pressure ResearchGuangzhou, ChinaParallel Group RCT6 months40AllopurinolNo treatmentTable 2**Study population characteristics**First author (Ref. No.)PopulationBL RAAS blockadeTx ageCt ageTx gender (F:M or % male)Ct gender (F:M or % male)Tx SUA baseline (mg/dL)Ct SUA baseline (mg/dL)Katholi \[[@CR51]\]sCr 1.4-2.0 mg/dl and rec contrastExcluded60 ± 4 (NMg), 61 ± 3 (LoMg)59 ± 5 (NMg), 63 ± 4 (LoMg)Not reportedNot reportedNot reportedNot reportedPerez-Ruiz \[[@CR56]\]Chronic Gout with CrCl 20-80Not reported60.9 ± 12.867.3 ± 9.59Not reportedNot reported9.35 ± 1.968.96 ± 1.84Kamper \[[@CR50]\]HTN CsA Renal TrMinorityM median age 47, W median age 47N/A10:16N/A7.90 (median), 4.87-11.60 (range)N/ASchmidt \[[@CR53]\]HTN CsA Renal TrNot reported58 ± 12N/A1:12N/A7.8 ± 2.27.8 ± 1.8Doehner \[[@CR35]\]LV dysfxn (EF \< 40%), hyperUA \>400 umol/LNot reported68 ± 269 ± 3100% male100% male8.99 ± 0.379.88 ± 0.62Chanard \[[@CR54]\]HTN CsA Renal TrNot reported45.2 ± 9.948.2 ± 11.57:178:168.11 ± 1.667.56 ± 1.65Siu \[[@CR48]\]sCr 120-400 umol/LMajority47.7 ± 12.948.8 ± 16.89:413:159.75 ± 1.189.92 ± 1.68Liu \[[@CR36]\]CKD (120-400 umol/L) and hyperUANot reported45.6 ± 12.546.5 ± 13. 88:1610:139.73 ± 0.209.92 ± 0.26Sarris \[[@CR34]\]hyperUA \> 7 mg/dL, mild-mod CKD, sCr \>1.5, \<3.0 mg/dLNot reported49.2 ± 17.350.4 ± 15.88:1011:78.88 ± 1.269.16 ± 1.46Lei \[[@CR40]\]CKD with hyperUANot reported48.6 ± 10.249.5 ± 9.89:209:198.84 ± 1.458.70 ± 1.41Malaguarnera \[[@CR55]\]hyperUA, 65-85 yrs, sCr 2.5 mg/dlApproximately half75.6 ± 8.476.4 ± 8.115:512:610.9 ± 2.910.3 ± 3.1Nouri-Majalan \[[@CR52]\]Pts undergoing CABG and eGFR \< 60Not reported65 ± 9.561 ± 7.9013:1716:14Not reportedNot reportedDeng \[[@CR37]\]CKDNot reported60.0 ± 11.158.8 ± 9.415:1414:188.59 ± 1.018.93 ± 0.96Goicoechea \[[@CR44]\]CKD Stage 3-5Majority72.1 ± 7.971.4 ± 9.5Not reportedNot reported7.8 ± 2.17.3 ± 1.6Momeni \[[@CR46]\]T2DM NephropathyMajority56.3 ± 10.659.1 ± 10.611:911:95.96 ± 1.216.5 ± 2.2Shen \[[@CR38]\]CKD with hyperUANot reported47.1 ± 11.847.6 ± 12.48:189:179.01 ± 1.388.89 ± 1.50Kao \[[@CR45]\]LVH and CKD Stage 3Majority70.6 ± 6.973.7 ± 5.359% male46% male7.39 ± 1.57.06 ± 1.3Tan \[[@CR39]\]T2DM nephropathy eGFR, 30-60 ml/min/1.73 m^2^Majority59.3 ± 9.258.6 ± 8.335:3733:358.93 ± 0.968.60 ± 1.01Shi \[[@CR47]\]IgA nephropathy and hyperUAExcluded39.7 ± 10.040.1 ± 10.88:1310:97.9 ± 1.17.8 ± 1.1

Study results {#Sec9}
-------------

Pooled estimate of eGFR was in favour of allopurinol with a mean difference (MD) of 3.2 ml/min/1.73 m^2^, 95% confidence interval (CI) 0.16-6.2 ml/min/1.73 m^2^, p = 0.039. Heterogeneity was measured with a Q-value of 6.95 and I^2^ of 42.5, p = 0.138. We performed a sensitivity analysis excluding studies in which we had calculated eGFR from serum creatinine: in this analysis, the tendency was in the same direction but the results did not meet formal statistical significance. Pooling of serum creatinine also favoured allopurinol with a mean difference of 0.63 mg/dL, 95% CI 0.43-0.83 mg/dL. As expected, a statistically significant reduction in serum uric acid was found with a MD of 2.8 mg/dL, 95% CI 2.3-3.4 mg/dL, p \< 0.001. Notably reductions were found for both pooled estimates of systolic (MD 6.6 mmHg, 95% CI 2.0-11.1 mmHg) and diastolic blood pressure (MD 2.1 mmHg, 95% CI 0.50-3.7 mmHg). Proteinuria showed a tendency towards benefit, again favouring allopurinol (Figure [2](#Fig2){ref-type="fig"}). A funnel plot was completed for serum creatinine, which showed mild asymmetry consistent with publication bias (Figure [3](#Fig3){ref-type="fig"}).Figure 2Forest plots.Figure 3Risk of bias assessment.

We did not meta-analyze trials of less than three months' duration, because we thought it biologically implausible that effects would be observable so rapidly. Three trials with less than one month of follow up did not show statistically significant differences in renal function \[[@CR50]-[@CR53]\]. There were three studies of between one and three months' duration: uricosuric amlodipine compared to tertatolol showed higher eGFR in the group treated with amlodipine \[[@CR54]\]; creatinine clearance improved following a single dose infusion of rasburicase compared to placebo \[[@CR55]\]; and there was a tendency towards higher eGFR in a comparison of benzbromarone to allopurinol \[[@CR56]\].

There were insufficient data on adverse events, incidence of ESRD and cardiovascular events for meta-analysis. One study reported cardiovascular event rates finding a statistically significant reduction in cardiovascular risk comparing allopurinol to usual therapy after 24 months of follow-up (HR 0.29, 95% CI 0.09-0.86, p = 0.026) \[[@CR44]\]. No serious adverse events were noted in any of the included studies, specifically allopurinol hypersensitivity syndrome, toxic epidermal necrolysis or Steven-Johnson syndrome.

Risk of bias of included studies {#Sec10}
--------------------------------

Overall, study quality was variable (Figure [4](#Fig4){ref-type="fig"}). The internal validity of the included RCTs was difficult to assess as most studies omitted important methodological details. Notably, some studies did not use an intention-to-treat analysis. We were not able to report quality features in one study as it was available in abstract form only \[[@CR34]\]. Although a few of the studies were not placebo-controlled, we did not assess this as a high risk of bias per se since our outcomes of interest were objective.Figure 4Funnel plot.

Discussion {#Sec11}
==========

In our meta-analysis of RCTs of treatments to lower serum urate, we observed a small but potentially clinically important and statistically significant improvement in eGFR and serum creatinine, favouring allopurinol. There were also statistically significant reductions in systolic and diastolic blood pressure, and serum uric acid, as expected. A tendency towards benefit for proteinuria was shown as well.

Strengths of our review include its comprehensiveness and robust methodology. Limitations include the quality of our individual studies. Many of our included trials are small, single-centre studies with relatively short duration of follow-up. Two of our longest studies both had no placebo arm and were open-label trials \[[@CR44],[@CR48]\]. Also, two of our included trials did not report estimates of GFR; we converted serum creatinine into eGFR values using mean demographic variables, which is a reasonable assumption, but one which increases measurement area for these values. We conducted a sensitivity analysis on data that did not require these calculations, finding a similar result but one that lacked statistical significance.

We are aware of two recently published systematic reviews of this question \[[@CR42],[@CR41]\]. Bose and colleagues conducted a comprehensive search of the English literature and similarly identified the scarcity of robust data on which to draw conclusions. Wang and colleagues searched up to December 2011, however, they incorporated Chinese databases resulting in several non-English RCTs. Our meta-analysis adds to these by the more recent search date, including data on calculated eGFR from studies that reported only serum creatinine as well as reporting effects on blood pressure as an outcome. The Cochrane Renal Group also is in the process of conducting a review; their protocol is published \[[@CR30]\].

We do not know the mechanism by which allopurinol, or other urate-lowering therapy, is nephroprotective. Xanthine oxidase produces reactive oxygen species (ROS) and its inhibition with allopurinol may reduce oxidative stress \[[@CR33]\]. However, it is difficult to differentiate if such effects are secondary to the lowering of uric acid per se or inhibition of a ROS-producing enzyme.

In rats with remnant kidneys, oxonic-acid induced hyperuricemia accelerates glomerulosclerosis and tubulointerstitial fibrosis \[[@CR57],[@CR58]\]. Micropuncture studies in these same models suggest preglomerular arteriolar disease alters renal autoregulation, resulting in systemic and glomerular hypertension \[[@CR59]\]. In all of these studies, correction of the hyperuricemic state with a uricosuric agent can significantly improve blood pressure control, decrease proteinuria, and slow progression of kidney disease \[[@CR57],[@CR59],[@CR58]\]. Further studies may consider concurrently measuring markers of oxidative stress, inflammation, and blood pressure parameters to better understand mechanisms of a potential benefit.

We also take note of the recently published long-term follow up study of Goicoechea et al., lending further support to treating urate in CKD. Their adjusted hazard ratios for reduction of renal and cardiovascular events were 0.32, with a 95% CI of 0.15-0.69, p = 0.004, and 0.43 with a 95% CI of 0.21-0.88, p = 0.02, respectively. Notably, the definition of their renal endpoints entailed initiation of dialysis therapy and doubling of serum creatinine. However, again their data is limited by small sample size and single-centre design. Also, as the study was a post-hoc analysis, it did not require patients to adhere to previous randomly allocated treatment arms \[[@CR60]\].

Conclusions {#Sec12}
===========

Though the data we summarize here are suggestive and encouraging, using allopurinol in clinical practice to delay progression of CKD would be premature. Given these limitations, studies powered to measure reduction in patient-important renal composites are necessary, and are in progress \[[@CR61]-[@CR63]\].

Additional file {#Sec13}
===============

Additional file 1:**Database search strategies.**
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